Clinical Trial Update: Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib in patients undergoing surgery for metastatic kidney cancer was terminated; results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-12-31